Novel triazole antifungal drugs: Focus on isavuconazole, ravuconazole and albaconazole

Current Opinion in Investigational Drugs

Volumn 11, Issue 2, 2010, Pages 164-174

  Pasqualotto, Alessandro C ^a,b   Thiele, Karoline O ^c   Goldani, Luciano Z ^a,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Hospital Dom Vicente Scherer   (Brazil)

^c UNIVERSIDADE FEEVALE   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Albaconazole; Antifungal agent; Azole; Isavuconazole; Ravuconazole

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ALBACONAZOLE; BMS 379224; CYCLOSPORIN; E 1224; FLUCONAZOLE; ISAVUCONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE; WARFARIN; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; CLINICAL TRIAL; CROSS RESISTANCE; DIZZINESS; DRUG DOSE COMPARISON; DRUG TOLERABILITY; FUSARIUM; HEADACHE; HUMAN; MYCOSIS; NAUSEA; REVIEW; RHINITIS; RHINOPHARYNGITIS; SCEDOSPORIUM; ZYGOMYCETES; ANIMAL; DRUG EFFECT; FUNGUS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANIMALS; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; NITRILES; PYRIDINES; QUINAZOLINES; THIAZOLES; TRIAZOLES;

EID: 77649178125     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Zonios DI, Bennett JE: Update on azole antifungals. Semin Respir Crit Care Med (2008) 29(2):198-210.
2. Stevens D: Itraconazole in cyclodextrin solution. Pharmacotherapy (1999) 19(5):603-611.
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R et al: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 347(6):408-415.
4. Pasqualotto AC, Xavier MO, Andreolla HF, Linden R: Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf (2010) 9(1):125-137.
5. Johnson LB, Kauffman CA: Voriconazole: A new triazole antifungal agent. Clin Infect Dis (2003) 36(5):630-637.
6. Courtney R, Radwanski E, Lim J, Laughlin M: Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother (2004) 48(3):804-808.
7. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M et al: Posaconazole vs. fuconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 356(4):348-359.
8. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais De Azevedo W, Reddy V, Boparai N, Pedicone L et al: Posaconazole or fuconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med (2007) 356(4):335-347.
9. PDR staff (Ed): 2006 Redbook: Pharmacy's Fundamental Reference. Thomson PDR, Montvale, NJ, USA (2006).
10. Seifert H, Aurbach U, Stefanik D, Cornely O: In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother (2007) 51(5):1818-1821.
11. Pasqualotto AC, Denning DW: New and emerging treatments for fungal infections. J Antimicrob Chemother (2008) 61 (Suppl 1):i19-i30.
12. Ueda Y, Barbour N, Bronson JJ, Connolly TP, Dali M, Gao Q, Golik J, Huang S, Hudyma TW, Kang S, Knipe J et al: BMS-379224, a water-soluble prodrug of ravuconazole. Interscience Conference on Antimicrobial Agents and Chemotherapy (2002) 42:Abs F-817.
13. Eisai Co Ltd: Eisai and DNDi enter collaboration and license agreement to develop new drug for Chagas disease. Press Release (2009): September 29.
14. Bartroli J, Turmo E, Algueró M, Boncompte E, Vericat ML, Conte L, Ramis J, Merlos M, García-Rafanell J, Forn J: New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J Med Chem (1998) 41(11):1869-1882.
15. Ramos G, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL: In vitro comparative activity of UR-9825, itraconazole and fuconazole against clinical isolates of Candida spp. J Antimicrob Chemother (1999) 44(2):283-286.
16. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C: Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother (2006) 50(1):279-285.
17. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle M: Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother (2006) 50(1):286-293.
18. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW: Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: Mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother (2009) 53(8):3453-3461.
19. Schmitt-Hoffmann A, Ross B, Heep M, Brown T: Steady-state bioavailability of oral isavuconazole in healthy volunteers. European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany (2007) 17:Abs P987.
20. Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Roehrle M, Schoetzau A, Simmens U: No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. Interscience Conference on Antimicrobial Agents and Chemotherapy (2008) 48:Abs A-008.
21. Cornely O, Böhme A, Heep M, Schmitt-Hoffmann A, Ullmann A: Pharmacokinetics, safety and tolerability results of a dose escalation study of isavuconazole in neutropenic patients. Interscience Conference on Antimicrobial Agents and Chemotherapy (2008) 48:Abs M-2137.
22. Schmitt-Hoffmann A, Roos B, Spickermann J, Heep M, Peterfaí E, Edwards DJ, Stoeckel K: Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother (2009) 53(11):4885-4890.
23. Olsen SJ, Mummaneni V, Rolan P, Norton J, Grasela DM: Ravuconazole single ascending oral dose study in healthy subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy (2000) 40:Abs A-838.
24. Grasela DM, Olsen SJ, Mummaneni V, Rolan P, Christopher L, Norton J, Hadjilambris OW, Marino MR: Ravuconazole: Multiple ascending oral dose study in healthy subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy (2000) 40:Abs A-839.
25. Bello A, Russo R, Grasela D, Salahudeen I: Pharmacokinetics of intravenous BMS-379224 (pro-drug of ravuconazole) in healthy male subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy (2003) 43:Abs A-1567.
26. Izquierdo I, Lurigados C, Perez I, Tumo E, Ramis J: First administration into man of UR-9825: A new triazole class of antifungal agent. European Confederation of Medical Mycology Congress, Barcelona, Spain (2000) 6:Abs P2-004.
27. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Brown T, Spickermann J, Allison M, Heep M: Effect of BAL8557, a water-soluble azole pro-drug, on the pharmacokinetics of S-and R-warfarin. Congress of the International Society for Human and Animal Mycology, Paris, France (2006) 16:Abs P-0321.
28. Schmitt-Hoffmann A, Roos B, Allison M, Heep M: Effect of isavuconazole on the pharmacokinetics and the pharmacodynamics of warfarin. Interscience Conference on Antimicrobial Agents and Chemotherapy (2007) 47:Abs A-776.
29. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Brown T, Spickermann J, Roehrle M, Heep M: Effect of BAL8557, a water-soluble azole pro-drug, on the pharmacokinetics of cyclosporine. Congress of the International Society for Human and Animal Mycology, Paris, France (2006) 16:Abs P-0136.
30. Schmitt-Hoffmann A, Roos B, Sauer J, Maares J, Spickermann J, Iersel MP, Heep M: Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 and rifampicin. Congress of the International Society for Human and Animal Mycology, Paris, France (2006) 16:Abs P-0319.
31. Mummaneni V, Geraldes M, Hadjilambris OW, Ouyang Z, Uderman H, Marino MR: Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects. Interscience Conference on Antimicrobial Agents and Chemotherapy (2000) 40:Abs A-841.
32. Viljoen JJ, Mitha I, Heep M, Ghannoum M: Effcacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fuconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) 45:Abs LB2-32.
33. Bartroli X, Uriach J: A clinical multicenter study comparing effcacy and tolerability between fve single oral doses of albaconazole and fuconazole 150 mg single dose in acute vulvovaginal candidiasis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) 45:Abs M-722.
34. Messer SA, Jones RN, Fritsche TR: International surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol (2003) 44(5):1782-1787.
35. Alves SH, Da Matta DA, Azevedo AC, Loreto ES, Boff E, Santurio JM, Guarro J: In vitro activities of new and conventional antimycotics against fuconazole-susceptible and non-susceptible Brazilian Candida spp. isolates. Mycoses (2006) 49(3):220-225.
36. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ: Cross-resistance between fuconazole and ravuconazole and the use of fuconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J Clin Microbiol (2004) 42(7):3137-3141.
37. Mouton JW, Verwij PE, Warn P, Denning D, Heep M, Isham N, Ghannoum M: In vitro activity of a new triazole BAL4815 against Candida isolates with decreased fuconazole susceptibility. Trends in Medical Mycology, Berlin, Germany (2005) 2:Abs P021.
38. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Rodriguez-Tudela JL: In vitro activities of ravuconazole and four other antifungal agents against fuconazole-resistant or susceptible clinical yeast isolates. Antimicrob Agents Chemother (2004) 48(8):3107-3111.
39. Arechavala AI, Bianchi MH, Robles AM, Santiso G, Negroni R: Identifcation and susceptibility against fuconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge. Rev Iberoam Micol (2007) 24(4):305-308.
40. Warn PA, Sharp A, Denning DW: Dose response curves and dose fractionation studies with BAL8557 in a murine model of disseminated candidiasis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) 45:Abs B-47.
41. Te Dorsthorst D, Verweij PE, Meis JF, Mouton JW: Pharmacodynamics of BAL4815: A new azole antifungal in a mouse model of systemic infection. Interscience Conference on Antimicrobial Agents and Chemotherapy (2004) 44:Abs A-1874.
42. Warn PA, Parmer M, Jayesh M, Denning DW, Hope WW: Pharmacokinetics (PK) and pharmacodynamics (PD) of isavuconazole in a murine model of disseminated candidiasis (DC). Interscience Conference on Antimicrobial Agents and Chemotherapy (2008) 48:Abs M-2140.
43. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA: Effcacy of isavuconazole, voriconazole and fuconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother (2009) 63(1):161-166.
44. Andes D, Marchillo K, Stamstad T, Conklin R: In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother (2003) 47(4):1193-1199.
45. Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K: Effcacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother (1996) 40(10): 2243-2247.
46. Mikamo H, Yin XH, Hayasaki Y, Shimamura Y, Uesugi K, Fukayama N, Satoh M, Tamaya T: Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy (2002) 48(1):7-9.
47. Warn PA, Sharp A, Majithiya JB, Parmar A, Denning DW: In vitro post antibiotic effect of isavuconazole, voriconazole and amphotericin B against a strain of C. Albicans with concentration-dependent pharmacokinetics in a murine model and susceptibility of strains for murine kidneys post infection. European Conference on Clinical Microbiology and Infectious Diseases, Barcelona, Spain (2008) 18:Abs P2177.
48. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA et al: Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 46(3):327-360.
49. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL: Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 41(6):1364-1368.
50. Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW: Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents (2006) 28(5):450-453.
51. Howard SJ, Moore CB, Denning DW: Azole resistance in Aspergillus niger. Advances Against Aspergillosis, Athens, Greece (2006) 2:Abs P071.
52. Diekema DJ, Messer S, Hollis R, Boyken L, Tendolkar S, Kroeger J, Pfaller MA: Patterns of triazole cross-resistance/susceptibility among a large collection of clinical isolates of Aspergillus.Interscience Conference on Antimicrobial Agents and Chemotherapy (2007) 47:Abs M-523.
53. Verweij PE, Van Der Lee HAL, Kuijpers J, Snelders E, Rijs AJMM, Melchers WJG: Epidemiology of multiple-triazole-resistant Aspergillus fumigatus. Interscience Conference on Antimicrobial Agents and Chemotherapy (2007) 47:Abs M-2018.
54. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin D, Denning DW: Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis (2009) 15(7):1068-1076.
55. Baddley JW, Kano R, Brandt ME, Marr KA, Kauffman CA, Andes DA, Moser AS, Pappas PG, Balajee SA: Molecular characterization and antifungal susceptibilities of Aspergilli from the Transplant-Associated Infection Surveillance Network (TRANSNET). Interscience Conference on Antimicrobial Agents and Chemotherapy (2007) 47:Abs M-2019.
56. Guinea J, Jensen J, Peláez T, Torres-Narbona M, Bouza E: In vitro activity of isavuconazole (BAL4815) and voriconazole against 443 isolates of Aspergillus spp. Trends in Medical Micology, Torino, Italy (2007) 3:Abs P026.
57. Warn PA, Sharp A, Denning DW: In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother (2006) 57(1):135-138.
58. Perkhofer S, Lechner V, Lass-Florl C: In vitro activity of isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother (2009) 53(4):1645-1647.
59. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA: Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of flamentous fungi. J Clin Microbiol (2003) 41(8):3623-3626.
60. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ: Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol (2002) 40(9):3204-3208.
61. Moore CB, Walls CM, Denning DW: In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother (2000) 44(2):441-443.
62. Pfaller MA, Messer SA, Hollis RJ, Jones RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other flamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother (2002) 46(4):1032-1037.
63. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL: In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte flamentous fungi. Antimicrob Agents Chemother (2005) 49(12):5136-5138.
64. Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K: In vitro and in vivo activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother (1996) 40(10):2237-2242.
65. Capilla J, Ortoneda M, Pastor FJ, Guarro J: In vitro antifungal activities of the new triazole UR-9825 against clinically important flamentous fungi. Antimicrob Agents Chemother (2001) 45(9):2635-2637.
66. Warn PA, Mosquera J, Sharp A, Denning DW: In vivo effcacy of the triazole BAL8557 (BAL) compared to voriconazole (VOR), itraconazole (ITC) and caspofungin (CAS) by a new qPCR and quantitative culture in neutropenic murine model of Aspergillus favus. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) 45:Abs B-48.
67. Warn PA, Parmar A, Sharp A, Denning DW: Dose response in neutropenic mice with disseminated infection of multiple strains of Aspergillus fumigatus with widely varying MIC and MFC values treated with isavuconazole. European Conference of Clinical Microbiology and Infectious Diseases, Munich, Germany (2007) 17:Abs P-1951.
68. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF: Effcacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother (2002) 49(2):353-357.
69. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP et al: Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis (2005) 41(5):634-653.
70. Rogers TR: Treatment of zygomycosis: Current and new options. J Antimicrob Chemother (2008) 61(Suppl 1):i35-i40.
71. Lass-Flörl C: The changing face of epidemiology of invasive fungal disease in Europe. Mycoses (2009) 52(3):197-205.
72. Triflio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS et al: Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant (2007) 39(7):425-429.
73. Pagano L, Gleissner B, Fianchi L: Breakthrough zygomycosis and voriconazole. J Infect Dis (2005) 192(8):1496-1497.
74. Oren I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis (2005) 40(5):770-771.
75. Kobayashi K, Kami M, Murashige N, Kishi Y, Fujisaki G, Mitamura T: Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica (2004) 89(11):ECR42.
76. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA: Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 39(5): 743-746.
77. Marty FM, Cosimi LA, Baden LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med (2004) 350(9):950-952.
78. Greenberg RN, Mullane K, van Burik JA, Raad I, Abzug MJ, Anstead G, Herbrecht R, Langston A, Marr KA, Schiller G, Schuster M et al: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 50(1):126-133.
79. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP: Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis (2006) 42(7):e61-e65.
80. Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis (2008) 47(3):364-371.
81. Warn P, Sharp A, Denning D: In vitro activity of BAL4815 against Zygomycetes. International Society for Human and Animal Mycology, Paris, France (2006):Abs P-0158.
82. Verweij PE, González GM, Wiedrhold NP, Lass-Flörl C, Warn P, Heep M, Ghannoum MA, Guinea J: In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother (2009) 21(3):272-281.
83. Verweij PE, Van der Lee HAL, Rijs AJMM: Isavuconazole is active against Zygomycetes in vitro. Trends in Medical Mycology, Torino, Italy (2007) 3:Abs P051.
84. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E: In vitro antifungal activities of isavuconazole, voriconazole and fuconazole against 1007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother (2008) 52(4):1396-1400.
85. Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J: In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect (2003) 9(12): 1250-1252.
86. Nucci M, Anaissie E: Fusarium infections in immuno-compromised patients. Clin Microbiol Rev (2007) 20(4):695-704.
87. Sekhon AS, Padhye AA, Garg AK, Ahmad H, Moledina N: In vitro sensitivity of medically signifcant Fusarium species to various antimycotics. Chemotherapy (1994) 40(4):239-244.
88. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 36(9):1122-1131.
89. Szekely A, Johnson EM, Warnock DW: Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol (1999) 37(5):1480-1483.
90. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL: Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and flamentous fungi. Antimicrob Agents Chemother (2006) 50(3):917-921.
91. Ghannoum M, Isham N: Antifungal activity of BAL4815, a novel azole against dermatophytes and emerging non-dermatophyte fungi including Zygomycetes. Interscience Conference on Antimicrobial Agents and Chemotherapy (2005) 45: Abs M-1623.
92. González GM: In vitro activities of isavuconazole against opportunistic flamentous and dimorphic fungi. Med Mycol (2009) 47(1):71-76.
93. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzón A, Mellado E, Rodríguez-Tudela JL: Antifungal susceptibility profle of clinical Fusarium spp. isolates identifed by molecular methods. J Antimicrob Chemother (2008) 61(4):805-809.
94. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J: In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis (2004) 48(1):69-71.
95. Pasqualotto AC, Bittar AE, de Quadros M, Severo LC: Cryptococcal cellulitis in a renal transplant patient. Nephrol Dial Transplant (2005) 20(9):2007-2008.
96. Pasqualotto AC, Severo CB, Oliveira FM, Severo LC: Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev Iberoam Micol (2004) 21(3):143-146.
97. Severo LC, de Mattos Oliveira F, Londero AT: Cryptococcosis due to Cryptococcus neoformans var. gattii in Brazilian patients with AIDS. Report of three cases. Rev Iberoam Micol (1999) 16(3):152-154.
98. dos Santos IS, Severo LC, Pasqualotto AC: Susceptibility of clinical isolates of Cryptococcus neoformans and Cryptococcus gattii to voriconazole. European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland (2006) 16:Abs R2163.
99. Trilles L, Fernández-Torres B, Lazéra Mdos S, Wanke B, Guarro J: In vitro antifungal susceptibility of Cryptococcus gattii. J Clin Microbiol (2004) 42(10):4815-4817.
100. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M: Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother (2005) 56(6):1144-1147.
101. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ: Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol (2005) 43(5):2163-2167.
102. Morera-López Y, Torres-Rodríguez JM, Jiménez-Cabello T, Baró-Tomás T: Cryptococcus gattii: In vitro susceptibility to the new antifungal albaconazole versus fuconazole and voriconazole. Med Mycol (2005) 43(6):505-510.
103. Thompson GR 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF: Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2009) 53(1):309-311.
104. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF: In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 52(4):1580-1582.
105. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN: In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 44(10):2883-2886.
106. Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK J r, Bartroli J, Perfect JR: In vitro and in vivo effcacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 48(2):384-387.
107. Groll AH, Walsh TJ: Uncommon opportunistic fungi: New nosocomial threats. Clin Microbiol Infect (2001) 7(Suppl 2):8-24.
108. Husain S, Alexander BD, Munoz P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Baumgarten K, Yu CM et al: Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis (2003) 37(2):221-229.
109. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E: Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect (2004) 10 (Suppl 1):48-66.
110. Johnson EM, Szekely A, Warnock DW: In vitro activity of voriconazole, itraconazole and amphotericin B against flamentous fungi. J Antimicrob Chemother (1998) 42(6):741-745.
111. Cuenca-Estrella M, Ruiz-Díez B, Martínez-Suárez JV, Monzón A, Rodríguez-Tudela JL: Comparative in vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolifcans and Scedosporium apiospermum. J Antimicrob Chemother (1999) 43(1):149-151.
112. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 46(1):62-68.
113. Gilgado F, Serena C, Cano J, Gené J, Guarro J: Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother (2006) 50(12):4211-4213.
114. Capilla J, Yustes C, Mayayo E, Fernández B, Ortoneda M, Pastor FJ, Guarro J: Effcacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolifcans infection in rabbits. Antimicrob Agents Chemother (2003) 47(6):1948-1951.
115. Bartlett MS, Queener SF, Shaw MM, Richardson JD, Smith JW: Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob Agents Chemother (1994) 38(8):1859-1861.
116. Utili R, Durante-Mangoni E, Basilico C, Mattei A, Ragone E, Grossi P: Effcacy of caspofungin addition to trimethoprim-sulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation (2007) 84(6):685-688.
117. Hof H, Schnülle P: Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated effciently with caspofungin. Mycoses (2008) 51(Suppl 1):65-67.
118. Powles MA, Liberator P, Anderson J, Karkhanis Y, Dropinski JF, Bouffard FA, Balkovec JM, Fujioka H, Aikawa M, McFadden D, Schmatz D: Effcacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother (1998) 42(8):1985-1989.
119. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr: Characterization of a lanosterol 14 a-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol (2003) 29(2): 232-238.
120. Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P, Patel R, McNicholas PM, Goldman M: Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fuconazole. J Antimicrob Chemother (2006) 57(6): 1235-1239.
121. Clemons KV, Martinez M, Calderon L, Stevens DA: Effcacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob Agents Chemother (2002) 46(3):922-924.
122. Thompson GR 3rd, Wiederhold NP, Sutton DA, Fothergill A, Patterson TF: In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother (2009) 64(1):79-83.
123. Ghannoum MA, Isham N: Antifungal activity of BAL4815, a novel azole, against dermatophytes. Trends in Medical Mycology, Berlin, Germany (2005) 2:Abs P009.
124. Nweze EI, Curfs-Breuker I, Janssen BGJ, De Hoog GS, Meis JF: In vitro activity of posaconazole with seven antifungal agents against 80 clinical and 15 environmental isolates of Exophiala dermatidis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2006) 46:Abs M-1588.
125. Serena C, Ortoneda M, Capilla J, Pastor FJ, Sutton DA, Rinaldi MG, Guarro J: In vitro activities of new antifungal agents against Chaetomium spp. and inoculums standardization. Antimicrob Agents Chemother (2003) 47(10):3161-3164.
126. Muñoz C, Giusiano AJ, Quindos G, Rojas G, Sosa F, Eraso MA: Triazolic antifungal activity against Malassezia strains. Trends in Medical Mycology, Torino, Italy (2007) 3:Abs P-043.
127. Welshenbaugh AR, Angulo D, Ghannoum M: Time kill activity of albaconazole against agents of onychomycosis and tinea capitis. Interscience Conference on Antimicrobial Agents and Chemotherapy (2007) 47:Abs M-1814.